Logo
Login
$CALC
$1.31 +$0.01 (0.77%) Close

Company Executives

Management Team

From the proxy statement filed Jul 23, 2026
Officer Age In this role Joined 2025 pay Source
A. Rachel Leheny, Ph.D. Also a director
Chief Executive Officer and Class II Director
 63 Not stated Not stated $895,410
Stephen Bardin, MBA
Chief Financial Officer
 36 Since 2024
2 years
 2024 Not reported
Michael J. Dunn, MBA
President and Chief Operating Officer
 70 Since 2023
3 years
 Not stated Not reported
Eric W. Roberts Also a director
Chief Business Officer, Class II Director and Vice Chairman of the Board
 62 Not stated Not stated $703,558
Sudarshan Hebbar, M.D.
Chief Medical Officer
 62 Since 2023
3 years
 Not stated $763,315
Kenneth A. Stauderman, Ph.D.
Chief Scientific Officer
 73 Since 2023
3 years
 Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Jul 23, 2026
Directors
8
serving now
Independent
Not stated
the proxy does not say
Average tenure
2.3 years
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards 2025 pay Source
A. Rachel Leheny
CEO
 63 2023
3 years
 Not stated None stated None stated Paid as CEO
Eric W. Roberts
Executive officer
 62 2023
3 years
 Not stated None stated None stated Not stated
Allan Shaw
62 2023
3 years
 Not stated
Audit Committee · Chair Compensation Committee · Chair Nominating and Corporate Governance Committee
None stated $87,547
Robert N. Wilson
85 2023
3 years
 Not stated None stated None stated $111,213
Alan Glicklich
65 2025
1 year
 Not stated
Audit Committee
None stated $105,214
Evgeny Zaytsev
58 2026
0 years
 Not stated
Compensation Committee
None stated Not stated
Frederic Guerard
54 2023
3 years
 Not stated
Compensation Committee Nominating and Corporate Governance Committee · Chair
Lenz Therapeutics Not stated
Fred Middleton Leaving at the meeting
Not stated Not stated Not stated
Audit Committee Compensation Committee
None stated $73,783

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

16 disclosed in the proxy filed Jul 23, 2026
Danforth Advisors, LLC
a company affiliated with Mr. Geffken, our acting chief financial officer until November 2024
$131,000 and $294,000
years ended December 31, 2025 and 2024

Consulting agreement for strategic and financial advice; fees paid to Danforth

With CalciMedica Open in proxy
SG Dan Equity
granted in connection with Mr. Geffken's services under the Danforth Consulting Agreement
Amount not stated
2024

Warrant to purchase 10,000 shares of common stock at $5.45 per share, granted May 17, 2024

Open in proxy
Deerfield Partners, L.P.
$ 4,999,967.81

Purchase in the 2024 Private Placement

Open in proxy
Soleus Capital entities
$ 3,000,000.60

Purchase in the 2024 Private Placement

Open in proxy
Sanderling Ventures entities
$ 2,600,002.56

Purchase in the 2024 Private Placement

Open in proxy
Stonepine Capital, LP
$ 1,999,997.85

Purchase in the 2024 Private Placement

Open in proxy
A. Rachel Leheny, Ph.D.
$ 400,004.17

Purchase in the 2024 Private Placement

Open in proxy
A. Rachel Leheny, Ph.D.
$ 149,999.41

Purchase in the 2026 Private Placement

Open in proxy
Alafi Capital Company, LLC
$ 2,834,999.93

Purchase in the 2026 Private Placement

Open in proxy
Bering Partners II, L.P.
$ 1,164,999.48

Purchase in the 2026 Private Placement

Open in proxy
Sanderling Venture Partners VI Co-Investment Fund, L.P.
$ 199,999.21

Purchase in the 2026 Private Placement

Open in proxy
Sudarshan Hebbar, M.D.
$ 99,999.60

Purchase in the 2026 Private Placement

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans